pre-update Archives

Publication

Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes

An analysis of reported hepatic abundances of CYP3A4 and 3A5 indicated that values determined by…

Danielle Pillsbury2007年10月1日

Publication

A Systematic Comparison of Software Dedicated to Meta-analysis of Causal Studies

Our objective was to systematically assess the differences in features, results, and usability of currently…

Danielle Pillsbury2007年9月10日

Publication

Modeling, Simulation, and the Critical Path

The benefits of modeling and simulation fall into two categories: Increased certainty in trial designs…

Danielle Pillsbury2007年9月6日

Publication

Inactivation of CYP2D6 by Methylenedioxymethamphetamine in Different Recombinant Expression Systems

Recombinantly expressed CYP450 systems (rCYPs) are often used to screen for irreversible/quasi-irreversible enzyme inhibitors during…

Danielle Pillsbury2007年9月1日

Publication

Theoretical Assessment of a New Experimental Protocol for Determining Kinetic Values Describing Mechanism (time)-based Enzyme Inhibition

We have shown previously that the conventional experimental protocol (CEP) used to characterise mechanism-based enzyme…

Danielle Pillsbury2007年7月1日

Publication

The Use of Mechanistic DM-PK-PD Modeling to Assess the Power of Pharmacogenetic Studies—CYP2C9 and Warfarin as an Example

The aim of this study was to assess the power of in vivo studies needed…

Danielle Pillsbury2007年7月1日

Publication

Kinetics of the Time-dependent Inactivation of CYP2D6 in Cryopreserved Human Hepatocytes by Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (MDMA) was investigated in cryopreserved human hepatocytes as a time-dependent inactivator (TDI) of CYP2D6…

Danielle Pillsbury2007年5月1日

Publication

The Problems in Scaling Adult Drug Doses to Children

Many drugs are unlicensed in children and consequently their doses have been scaled down from…

Danielle Pillsbury2007年3月15日

Publication

Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX-2 Inhibitor

The objectives of these analyses were to (1) develop a population pharmacokinetic/pharmacodynamic model for a…

Danielle Pillsbury2007年3月1日

Publication

Misuse of the Well-stirred Model of Hepatic Drug Clearance

The “well-stirred” model of hepatic drug clearance was first proposed by Gillette and established by…

Danielle Pillsbury2007年3月1日

Powered by Translations.com GlobalLink Web Software

pre-update

Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes

A Systematic Comparison of Software Dedicated to Meta-analysis of Causal Studies

Modeling, Simulation, and the Critical Path

Inactivation of CYP2D6 by Methylenedioxymethamphetamine in Different Recombinant Expression Systems

Theoretical Assessment of a New Experimental Protocol for Determining Kinetic Values Describing Mechanism (time)-based Enzyme Inhibition

The Use of Mechanistic DM-PK-PD Modeling to Assess the Power of Pharmacogenetic Studies—CYP2C9 and Warfarin as an Example

Kinetics of the Time-dependent Inactivation of CYP2D6 in Cryopreserved Human Hepatocytes by Methylenedioxymethamphetamine (MDMA)

The Problems in Scaling Adult Drug Doses to Children

Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX-2 Inhibitor

Misuse of the Well-stirred Model of Hepatic Drug Clearance

メルマガ登録

クイックアクセス

ソリューション

お問合せ